| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-13-2024 | 03-31-2024 | 10-Q | |
| 2 | 04-01-2024 | 12-31-2023 | 10-K | |
| 3 | 11-13-2023 | 09-30-2023 | 10-Q | |
| 4 | 09-15-2023 | 06-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The positive results from this preclinical study underscore Ketamir-2's potential as a superior alternative to traditional ...
Ruling removes potential complications for manufacturing, pre-clinical development, IND submission, clinical development, and u...
Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for ma...
